[ad_1]
hapabapa/iStock Editorial by way of Getty Photographs
Gross sales from Eli Lilly’s (NYSE:LLY) newly permitted weight reduction treatment, Zepbound, may attain $4.1B by 2031 within the U.S., a current report from knowledge analytics agency GlobalData signifies.
Based on the report, that’s about half the extent of rival Novo Nordisk’s (NVO) weight reduction remedy Wegovy may generate by that yr.
Each Wegovy and Zepbound additionally indicated for Kind 2 diabetes, as Ozempic and Mounjaro generated $8.6B and $482.5M in international gross sales in 2022, respectively.
GlobalData’s newest forecast comes shut on the heels of FDA approval of LLY’s GLP-1 receptor agonist, often known as tirzepatide, for continual weight administration in adults.
The Indiana-based pharma big plans to launch the product earlier than year-end at a month-to-month record worth of about $1,060, with a 20% low cost to Wegovy, often known as semaglutide. In October, GlobalData projected Wegovy gross sales within the U.S. may attain $8.1B by 2031.
“Zepbound is Eli Lilly’s first drug which is indicated for weight problems, and its arrival to the weight problems house is about to lift the competitors for Novo Nordisk’s Wegovy (semaglutide) as a gold-standard remedy,” Sara Reci, Senior Pharma Analyst at GlobalData, famous.
Regardless of hurdles to their uptake, equivalent to lack of insurance coverage protection and manufacturing constraints, pharma’s deal with discovering extra efficacious weight reduction medicine will propel this indication to a $27.6B worth within the U.S. by 2031, GlobalData stated, citing a patient-based forecast.
Different main drugmakers creating weight-loss medicine embrace Pfizer (PFE) and Amgen (AMGN). Final week, AstraZeneca (AZN) inked a a deal value as much as $2B with China-based biotech Eccogene to develop an oral, once-daily GLP-1 receptor agonist for circumstances together with weight reduction.
“Nonetheless, it’s anticipated that the competitors between Eli Lilly and Novo Nordisk to win affected person shares for this indication will likely be fierce and one to be careful for,” GlobalData’s Reci added.
[ad_2]
Source link
